CA1171862A - Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereof - Google Patents
Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereofInfo
- Publication number
- CA1171862A CA1171862A CA000411269A CA411269A CA1171862A CA 1171862 A CA1171862 A CA 1171862A CA 000411269 A CA000411269 A CA 000411269A CA 411269 A CA411269 A CA 411269A CA 1171862 A CA1171862 A CA 1171862A
- Authority
- CA
- Canada
- Prior art keywords
- compound
- formula
- useful
- preparation
- inflammatory agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
ABSTRACT
The compounds of formula where R is hydrogen or fluorine possess glucocorticoid activity, and are prepared by reacting a compound of the formula
The compounds of formula where R is hydrogen or fluorine possess glucocorticoid activity, and are prepared by reacting a compound of the formula
Description
J 7186~
The present invention relates to novel polycyclia fused pyrazole compounds, their use as anti-inflammatory agents, and a method of preparation thereof.
Typical glucocorticoid activity is rarely found in structures which do not po~sess an intact steroid nucleus. Such activity is found in naturally occurring steroids such as cortisone, hydrocortisone and aldosterone, as well as numerous synthetic modifications thereof, all containing the intact steroid nucleus. An example of a synthetic cortical steroid having high activity is a fluorophenylpyrazole derivative reported by Fried et al., J. Am. Chem. Soc. 85, 236 (1963), having the str~cture ~0 HO ~ .. CH3 \ N
F
The pre~ent invention relates to compound~
having the formula:
~ I
where R i8 hydrogen or fluorine.
A pharmaceutical composition for treating inflammation in mammals comprises an anti-inflammatorily effective amount of a compound of Formula I and a phar-maceutically acceptable carrier. One can reduce inflammation in a mammal by administering to said mammal an anti-inflammatorily effective amount of a compound of Formula I.
One can prepare a compound of Formula I by reacting a compound of the formula:
CH
~ 2 I/
wlth l,2,3-indantrione.
The intermediates of Formula II are prepared from a known starting material, 5-ethenyl-4,4a,7,8-g 1~1862 .
tetrahydro-4a-methyl-2(3H)-naphthalenone U.S. Patent 4,157,349, in acaordance with the following reactions:
CH3¦
~ HC0 ~H3 o=J ~ ~ ~ J NaOCH3 CH=CH2 ¦ NHNH
NOC ~ + ~ ) II
The trienone starting material is reacted with methyl formate in the presence of ~odlum methoxide in an inert solvent such as tetrahydrofuran to afford 5-ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2~31~)-naphthalenone, and th~ latter is then reacted with phenylhydrazine or 4-fluorophenylhydrazine or an aaid-additlon salt thereof in the presenae of acetic acid to give the compound of Formula II.
The reaction of a compound of Formula II with 1,2,3-indantrione takes place by heating the reactant8 in an in-rt solvent at a temperature betwo~n about 50 and 150C.
The compounds of Formula I exhibit an endocrinological profile characteristic of compounds po~se~alng glucocorticoid propertie~ and systemia and/or toplcal anti-inflammatory activity; cf. R.H. Silber. The Biology of Anti-inflammatory Steroide, Annal~ of the Now York Academy of Sciencos, Vol. 82, Art. 4, pp. 821-828.
When the compound~ of Formula I are adm~nistered orally to rat~ they cause a ~ignificant depre~sion in thymus weight, adrenal weight and body weight gain without a change in food consumptlon.
The compound of Formula I where R 18 F has also been found to possess oral glucocorticold actlvity by the l l 71862 liver glycogen deposition test and anti-inflammatory activity by the ~-tocopherol pouch test in rats.
The test procedures used to determine the biological activities of the compounds of the invention were carried out as follows:
Endocrine Profile: Mature female rats with an average body weight of 202 g and a body weight ra~ge of 15 g or less were medicated orally with test compound for 2 weeks. The test compound was prepared as a solution or suspension in 1~ gum tragacanth or 0.75% methyl cellulose.
On the day following the last medication, the rats were killed and the thymus and adrenal of each rat were removed, cleaned, and weighed. Body weights and food consumptions were also recorded.
Anti-inflammatory Activity (~-tocopherol pouch test): Male rats which weighed 120 g were selected for testing. A rapid subcutaneous injection of 25 mL of air was made between the scapulae of each rat. This resulted in the establishment of an airfilled pouch into which 0.5 mL of dl-~-tocopherol was inje~ted. The test compound was administered in daily oral dose~ for 7 days beginning on the day of pouch formation. The compound to be tested was su~pended in 1% gum tragacanth. Twenty-four hours after the last medication, the pouches were dissected free, and the fluid volume was mea8ured. The inhibition of liquid exudate is a mea~ure of the anti-inflammatory activity.
Glycogenic Activity: Mature male rats were bilaterally adrenalectomized 5 days prior to the test.
These rats were medicated orally with the test compound for 5 days. Seven hour~ ater the last medication, the rats ~which have been fasted overnight) were ane~thetized with sodium pentobarbital and a portion of one lobe of the liver was removed and frozen on dry ice for subsequent glycogen determination.
The compounds of the invention can be formulated for topical application by solution or disper~ion in a ! 1 71~6~
conventional pharmaceutically acceptable liquid, cream or ointment base. The effective ingredient is preferably presen~ in a concentration of 0.01% to 5.0% by weight.
The compounds of the invention can be formulated for oral administration in tablet or capsule form with conventional excipients. The active ingredient is pre-ferably present in an amount of 1 mg to 100 mg per unit dosage form.
The following examples will further illustrate the invention.
Example 1 (a) 5-Ethenyl-3-hydroxymethylene-4!4a,7,8-tetrahydro-4a-methyl-2~3H)-naphthalenone.
A solution of 50.0 g (0.265 mol) of 5-ethenyl-4, 4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone in 350 mL
of tetrahydrofuran was cooled to -5C. in an ice-methanol bath and stirred under nitrogen while 57.2 g (1.06 mol) of sodium methoxide was added. The resulting mixture was stirred for 30 min at -5~C. and then a solution of 114 mL
(1.85 mol) of methyl formate in 100 mL of tetrahydrofuran was added slowly. The mixture was ~tirred overnight at room temperature and then poured onto a mixture of ice-water (1500 mL) and 6N hydrochloric acid (265 mL). The product was extracted with ether and the combined extracts were wa~hed with water. The dried extract was dried over anhydrous magnesium sulfate and concentrated in vacuo to afford an oil. This oil was triturated with hexane (4 x 250 mL) and the combined triturates were dried over magnesium sulfate and concentrated in vacuo to afford 55.37 g of a red oil, consisting essentially of the above-entitled compound as established by proton NMR ~PMR) spectral data.
(b) l-Ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahYdro-9a-methyl-6H- na~htho~2,3-c~pyrazole (II; R - F).
4-Fluorophenylhydrazine hydrochloride (45.85 g~
0.282 mol) and sodium acetate (23.14 g, 0.282 mol) were added to a solution of 55.37 g (0.256 mol) of the product ~ t 71862 obtained in part (a) above in 225 mL of glacial acetic acid. The mixture was stirred overnight at room temperature and then concentrated in vacuo to afford a semi-solid.
This material was suspended in ether (1 L) and filtered to remove sodium chloride. The ether filtrate was washed with water (4 x 250 mL), saturated sodium bicarbonate ~until weakly basic) and saturated sodium chloride ~100 mL).
The extract was dried over anhydrous magnesium sulfate, decolorized with charcoal and concentrated in vacuo to afford an oil. This oil was triturated with 1:2 ether-hexane ~3 x 750 mL) to afford 69.58 g of a dark brown oil.
An analytical sample was prepared by using high-performance liquid chromatography with 1:3 ether-hexane as solvent.
The resulting yellow oil was triturated with pentane to afford 1-ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H -naphtho[2,3-c]pyrazole (II; R ~ F) as a yellow solid, m.p. 70-72C. with a consistent PMR spectrum.
(c) 8'-( ~ henyl)-2',3',5',6',11',11a'-hexahydro-lla'-me ~ indene[2,3'~-3~-pyrazolo~4",5":7',6'~-naphtho-[2 ~ ran-1,3-dione (I; R - F).
A mixture of 15.3 g (0.05 mol) of II ~R - F) (part b above) and 9.8 g ~0.055 mol) of 1,2,3-indantrione monohydrate ln 150 mL of xylene was refluxed for Z hours.
The cooled reaction mixture was filtered through silica gel and concentrated in vacuo. The residue wa~ crystallized ~rom ethanol to afford 7.19 g of I ~ R - F)as a tan solid, m.p. 210-211C. The proton NMR spectrum (PMR) was con-~l~tent with the assigned structure.
In the endocrine profile determination, Compound I ~R ~ F) at a dose level of 1 mg/kg caused a 61% reduction in thymus weight, 56% reduction in adrenal weight and 129%
reduction in body weight gain as compared with the controls.
In the ~-tocopherol pouch test, Compound I ~R ~ F) was actlve wlth ED50 ' 10 mg/kg. In the glycogenic activity te~t, Compound I ~R - E') at a dose level of 9 mg/kg/day x 5 produced a liver glycogen deposition value of 21.8 ~ 4.4 mg/g of tissue as compared to 2.2 ~ 0.04 mg/g for the -- I 1 7186~
;
vehicle ~1% gum tragacanth) alone.
Example 2 (a) l-Ethenyl-6-phenYl-3,4,9,9a-tetrahYdrO-ga-methyl-6H-naphtho~2,3-c]pyrazole tII; R = H) was prepared according to the procedure of Example 1, part ~), while substituting a molar e~uivalent amount of phenylhydrazine hydrochloride for the 4-fluorophenylhydrazine hydrochloride of that example. The product was characterized by its PMR ~pectrum.
(b) 2',3',5',6',11',11a'-Hexahydro-lla'-methyl-8'-phenylspiro 10 2H-indenel2,3']-3H-pyrazolor4",5":7',6'~naphtho~2,1-b]
pyran-l~3-dione (I; R = H).
A mixture of 14.42 g (0.05 mol) of II (R ~ H) (part a above) and 9.88 g (0.06 mol) of 1,2,3-indantrione monohydrate in 150 mL xylene wa~ refluxed for 2 hours, then allowed to stand at room temperature for 55 hours and filtered to afford a green solid. Thls green solid was di~olved in methylene dichloride, filtered through silica gel and the solvent removed in vacuo. The residue was triturated with ether to afford 10.95 g of I (R ~ H) as a yellow solid, m.p. 209-210C. The PMR spectrum was conslstent with the assigned structure.
In the endocrine profile determination, Compound I ~R ~ H) at a dose level of 5 mg/kg caused a 514 reduction ln thymu~ weight, 384 reductlon in adrenal weight, and 62~ reductlon in ~ody weight gain as compared with the controls. Compound I ~R ~ H) was inactlve in the ~-toaopherol pouch test at a dose level of 100 mg/kg.
The present invention relates to novel polycyclia fused pyrazole compounds, their use as anti-inflammatory agents, and a method of preparation thereof.
Typical glucocorticoid activity is rarely found in structures which do not po~sess an intact steroid nucleus. Such activity is found in naturally occurring steroids such as cortisone, hydrocortisone and aldosterone, as well as numerous synthetic modifications thereof, all containing the intact steroid nucleus. An example of a synthetic cortical steroid having high activity is a fluorophenylpyrazole derivative reported by Fried et al., J. Am. Chem. Soc. 85, 236 (1963), having the str~cture ~0 HO ~ .. CH3 \ N
F
The pre~ent invention relates to compound~
having the formula:
~ I
where R i8 hydrogen or fluorine.
A pharmaceutical composition for treating inflammation in mammals comprises an anti-inflammatorily effective amount of a compound of Formula I and a phar-maceutically acceptable carrier. One can reduce inflammation in a mammal by administering to said mammal an anti-inflammatorily effective amount of a compound of Formula I.
One can prepare a compound of Formula I by reacting a compound of the formula:
CH
~ 2 I/
wlth l,2,3-indantrione.
The intermediates of Formula II are prepared from a known starting material, 5-ethenyl-4,4a,7,8-g 1~1862 .
tetrahydro-4a-methyl-2(3H)-naphthalenone U.S. Patent 4,157,349, in acaordance with the following reactions:
CH3¦
~ HC0 ~H3 o=J ~ ~ ~ J NaOCH3 CH=CH2 ¦ NHNH
NOC ~ + ~ ) II
The trienone starting material is reacted with methyl formate in the presence of ~odlum methoxide in an inert solvent such as tetrahydrofuran to afford 5-ethenyl-3-hydroxymethylene-4,4a,7,8-tetrahydro-4a-methyl-2~31~)-naphthalenone, and th~ latter is then reacted with phenylhydrazine or 4-fluorophenylhydrazine or an aaid-additlon salt thereof in the presenae of acetic acid to give the compound of Formula II.
The reaction of a compound of Formula II with 1,2,3-indantrione takes place by heating the reactant8 in an in-rt solvent at a temperature betwo~n about 50 and 150C.
The compounds of Formula I exhibit an endocrinological profile characteristic of compounds po~se~alng glucocorticoid propertie~ and systemia and/or toplcal anti-inflammatory activity; cf. R.H. Silber. The Biology of Anti-inflammatory Steroide, Annal~ of the Now York Academy of Sciencos, Vol. 82, Art. 4, pp. 821-828.
When the compound~ of Formula I are adm~nistered orally to rat~ they cause a ~ignificant depre~sion in thymus weight, adrenal weight and body weight gain without a change in food consumptlon.
The compound of Formula I where R 18 F has also been found to possess oral glucocorticold actlvity by the l l 71862 liver glycogen deposition test and anti-inflammatory activity by the ~-tocopherol pouch test in rats.
The test procedures used to determine the biological activities of the compounds of the invention were carried out as follows:
Endocrine Profile: Mature female rats with an average body weight of 202 g and a body weight ra~ge of 15 g or less were medicated orally with test compound for 2 weeks. The test compound was prepared as a solution or suspension in 1~ gum tragacanth or 0.75% methyl cellulose.
On the day following the last medication, the rats were killed and the thymus and adrenal of each rat were removed, cleaned, and weighed. Body weights and food consumptions were also recorded.
Anti-inflammatory Activity (~-tocopherol pouch test): Male rats which weighed 120 g were selected for testing. A rapid subcutaneous injection of 25 mL of air was made between the scapulae of each rat. This resulted in the establishment of an airfilled pouch into which 0.5 mL of dl-~-tocopherol was inje~ted. The test compound was administered in daily oral dose~ for 7 days beginning on the day of pouch formation. The compound to be tested was su~pended in 1% gum tragacanth. Twenty-four hours after the last medication, the pouches were dissected free, and the fluid volume was mea8ured. The inhibition of liquid exudate is a mea~ure of the anti-inflammatory activity.
Glycogenic Activity: Mature male rats were bilaterally adrenalectomized 5 days prior to the test.
These rats were medicated orally with the test compound for 5 days. Seven hour~ ater the last medication, the rats ~which have been fasted overnight) were ane~thetized with sodium pentobarbital and a portion of one lobe of the liver was removed and frozen on dry ice for subsequent glycogen determination.
The compounds of the invention can be formulated for topical application by solution or disper~ion in a ! 1 71~6~
conventional pharmaceutically acceptable liquid, cream or ointment base. The effective ingredient is preferably presen~ in a concentration of 0.01% to 5.0% by weight.
The compounds of the invention can be formulated for oral administration in tablet or capsule form with conventional excipients. The active ingredient is pre-ferably present in an amount of 1 mg to 100 mg per unit dosage form.
The following examples will further illustrate the invention.
Example 1 (a) 5-Ethenyl-3-hydroxymethylene-4!4a,7,8-tetrahydro-4a-methyl-2~3H)-naphthalenone.
A solution of 50.0 g (0.265 mol) of 5-ethenyl-4, 4a,7,8-tetrahydro-4a-methyl-2(3H)-naphthalenone in 350 mL
of tetrahydrofuran was cooled to -5C. in an ice-methanol bath and stirred under nitrogen while 57.2 g (1.06 mol) of sodium methoxide was added. The resulting mixture was stirred for 30 min at -5~C. and then a solution of 114 mL
(1.85 mol) of methyl formate in 100 mL of tetrahydrofuran was added slowly. The mixture was ~tirred overnight at room temperature and then poured onto a mixture of ice-water (1500 mL) and 6N hydrochloric acid (265 mL). The product was extracted with ether and the combined extracts were wa~hed with water. The dried extract was dried over anhydrous magnesium sulfate and concentrated in vacuo to afford an oil. This oil was triturated with hexane (4 x 250 mL) and the combined triturates were dried over magnesium sulfate and concentrated in vacuo to afford 55.37 g of a red oil, consisting essentially of the above-entitled compound as established by proton NMR ~PMR) spectral data.
(b) l-Ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahYdro-9a-methyl-6H- na~htho~2,3-c~pyrazole (II; R - F).
4-Fluorophenylhydrazine hydrochloride (45.85 g~
0.282 mol) and sodium acetate (23.14 g, 0.282 mol) were added to a solution of 55.37 g (0.256 mol) of the product ~ t 71862 obtained in part (a) above in 225 mL of glacial acetic acid. The mixture was stirred overnight at room temperature and then concentrated in vacuo to afford a semi-solid.
This material was suspended in ether (1 L) and filtered to remove sodium chloride. The ether filtrate was washed with water (4 x 250 mL), saturated sodium bicarbonate ~until weakly basic) and saturated sodium chloride ~100 mL).
The extract was dried over anhydrous magnesium sulfate, decolorized with charcoal and concentrated in vacuo to afford an oil. This oil was triturated with 1:2 ether-hexane ~3 x 750 mL) to afford 69.58 g of a dark brown oil.
An analytical sample was prepared by using high-performance liquid chromatography with 1:3 ether-hexane as solvent.
The resulting yellow oil was triturated with pentane to afford 1-ethenyl-6-(4-fluorophenyl)-3,4,9,9a-tetrahydro-9a-methyl-6H -naphtho[2,3-c]pyrazole (II; R ~ F) as a yellow solid, m.p. 70-72C. with a consistent PMR spectrum.
(c) 8'-( ~ henyl)-2',3',5',6',11',11a'-hexahydro-lla'-me ~ indene[2,3'~-3~-pyrazolo~4",5":7',6'~-naphtho-[2 ~ ran-1,3-dione (I; R - F).
A mixture of 15.3 g (0.05 mol) of II ~R - F) (part b above) and 9.8 g ~0.055 mol) of 1,2,3-indantrione monohydrate ln 150 mL of xylene was refluxed for Z hours.
The cooled reaction mixture was filtered through silica gel and concentrated in vacuo. The residue wa~ crystallized ~rom ethanol to afford 7.19 g of I ~ R - F)as a tan solid, m.p. 210-211C. The proton NMR spectrum (PMR) was con-~l~tent with the assigned structure.
In the endocrine profile determination, Compound I ~R ~ F) at a dose level of 1 mg/kg caused a 61% reduction in thymus weight, 56% reduction in adrenal weight and 129%
reduction in body weight gain as compared with the controls.
In the ~-tocopherol pouch test, Compound I ~R ~ F) was actlve wlth ED50 ' 10 mg/kg. In the glycogenic activity te~t, Compound I ~R - E') at a dose level of 9 mg/kg/day x 5 produced a liver glycogen deposition value of 21.8 ~ 4.4 mg/g of tissue as compared to 2.2 ~ 0.04 mg/g for the -- I 1 7186~
;
vehicle ~1% gum tragacanth) alone.
Example 2 (a) l-Ethenyl-6-phenYl-3,4,9,9a-tetrahYdrO-ga-methyl-6H-naphtho~2,3-c]pyrazole tII; R = H) was prepared according to the procedure of Example 1, part ~), while substituting a molar e~uivalent amount of phenylhydrazine hydrochloride for the 4-fluorophenylhydrazine hydrochloride of that example. The product was characterized by its PMR ~pectrum.
(b) 2',3',5',6',11',11a'-Hexahydro-lla'-methyl-8'-phenylspiro 10 2H-indenel2,3']-3H-pyrazolor4",5":7',6'~naphtho~2,1-b]
pyran-l~3-dione (I; R = H).
A mixture of 14.42 g (0.05 mol) of II (R ~ H) (part a above) and 9.88 g (0.06 mol) of 1,2,3-indantrione monohydrate in 150 mL xylene wa~ refluxed for 2 hours, then allowed to stand at room temperature for 55 hours and filtered to afford a green solid. Thls green solid was di~olved in methylene dichloride, filtered through silica gel and the solvent removed in vacuo. The residue was triturated with ether to afford 10.95 g of I (R ~ H) as a yellow solid, m.p. 209-210C. The PMR spectrum was conslstent with the assigned structure.
In the endocrine profile determination, Compound I ~R ~ H) at a dose level of 5 mg/kg caused a 514 reduction ln thymu~ weight, 384 reductlon in adrenal weight, and 62~ reductlon in ~ody weight gain as compared with the controls. Compound I ~R ~ H) was inactlve in the ~-toaopherol pouch test at a dose level of 100 mg/kg.
Claims (3)
1. A process for preparing a compound of the Formula I
(hereinl where R is hydrogen or fluorine, which comprises reacting 1-ethenyl-6-(4-R-phenyl)-3,4-9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole with 1,2,3-indantrione.
(hereinl where R is hydrogen or fluorine, which comprises reacting 1-ethenyl-6-(4-R-phenyl)-3,4-9,9a-tetrahydro-9a-methyl-6H-naphtho[2,3-c]pyrazole with 1,2,3-indantrione.
2. A process according to claim 1, wherein R is fluorine.
3. A compound of the Formula I according to claim 1 or 2, when prepared by the process according to claim 1 or 2, respectively, or by an obvious chemical equivalent thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000411269A CA1171862A (en) | 1982-09-13 | 1982-09-13 | Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA000411269A CA1171862A (en) | 1982-09-13 | 1982-09-13 | Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1171862A true CA1171862A (en) | 1984-07-31 |
Family
ID=4123571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000411269A Expired CA1171862A (en) | 1982-09-13 | 1982-09-13 | Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereof |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA1171862A (en) |
-
1982
- 1982-09-13 CA CA000411269A patent/CA1171862A/en not_active Expired
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4183854A (en) | Thiazole compound | |
| CA1190226A (en) | Process for the preparation of novel pyrimido quinoxalines and their salts | |
| US4412995A (en) | Pentacyclic phenylpyrazole compounds as anti-inflammatory agents | |
| US4349559A (en) | Anti-inflammatory spiro-2H-indene-[2,3']-3H-pyrazolo[4",5":7',6']naphtho[2,1-b]pyran-1,3-dione derivatives | |
| US4349558A (en) | Anti-inflammatory 8H-phenanthro-[2,3-c]pyrazole derivatives | |
| CA1171862A (en) | Polycyclic fused pyrazole compounds, useful as anti- inflammatory agents, and preparation thereof | |
| US4307102A (en) | Phenanthro[2,3-c]pyrazole | |
| EP0058841B1 (en) | Phenylpyrazole compounds useful as anti-inflammatory agents and preparation thereof | |
| KR950006866B1 (en) | A process for ergoline esters preparation | |
| Wells et al. | Thietane 1, 1-Dioxides1 | |
| SU1508963A3 (en) | Method of producing 11beta-substituted steroids or their pharmaceutically or veterinarily acceptable salts | |
| JP2000169452A (en) | New aconitine-based compound and analgesic antiphlogistic medicine | |
| CA1178965A (en) | Polycyclic fused pyrazole compounds useful as anti- inflammatory agents and preparation thereof | |
| EP0240263B1 (en) | Indenopyrimidine derivatives | |
| EP0001029A1 (en) | Process for the preparation of 3-oximes of steroids | |
| EP0102404A1 (en) | Novel polycyclic fused pyrazole compounds useful as antiinflammatory agents and preparation thereof | |
| EP0103030A1 (en) | Polycyclic fused pyrazole compounds, useful as anti-inflammatory agents, and preparation thereof | |
| CS234003B2 (en) | Method of aryl-phenylindenes and aryl-phenylnaphalenes preparation | |
| NZ201822A (en) | Spiro-2h-indene(2,3')-3h-pyrazol(4",5":7',6')naptho(2,1-b)pyran-1,3-dione derivatives and pharmaceutical compositions | |
| US4374284A (en) | Antiulcer, antiinflammatory, and antiallergic agent comprising as the main ingredient olean-12-ene-3β, 30-diol which is devoid of side effects of glycyrrhetinic acid and a new process for preparation of olean-12-ene-3β, 30-diol | |
| WO1997021710A1 (en) | Use of heteroaromatic and tricyclic 1,4-dihydro-1,4-dioxo-naphthalene derivatives, resulting novel compounds and therapeutical use thereof | |
| US4454136A (en) | Substituted benzopyranotriazoles and antiallergic use | |
| NZ201821A (en) | Substituted phenanhro(2,3-c)pyrazole derivatives and pharmaceutical compositions | |
| Rosen et al. | Synthesis and biological activity of some 15-oxaestranes | |
| BE1004520A3 (en) | Asymmetric synthesis of derivatives furo [3,4-c] pyridine. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEC | Expiry (correction) | ||
| MKEX | Expiry |